Table 3.
Individual SNPs selected for association with bladder cancer risk by Kullback–Leibler distance
| Function | SNP | Genotype | Controls |
Cases |
Bladder cancer OR (95% CI) |
||
|---|---|---|---|---|---|---|---|
| N | % | N | % | ||||
| Detoxification | GSTZ1_02 | wt | 636 | 86 | 367 | 80 | 1.0 Ref. |
| g.Ex5−12G>A | het | 99 | 14 | 88 | 19 | 1.5 (1.1–2.1) | |
| p.G42R | var | 5 | 1 | 4 | 1 | 1.4 (0.4–5.3) | |
| any var | 104 | 15 | 92 | 20 | 1.5 (1.1–2.0) | ||
| Aldo/keto reductase | AKR1C3_35 | wt | 509 | 59 | 312 | 53 | 1.0 Ref. |
| PAH metabolism | g.*12259G>A | het | 315 | 37 | 238 | 41 | 1.3 (1.0–1.6) |
| var | 40 | 4 | 38 | 6 | 1.5 (0.9–2.4) | ||
| any var | 355 | 41 | 276 | 47 | 1.3 (1.0–1.6) | ||
| Pigmentation | TYR_02 | wt | 463 | 53 | 299 | 51 | 1.0 Ref. |
| Melanin production | g.IVS3−6895A>G | het | 322 | 37 | 255 | 43 | 1.2 (1.0–1.5) |
| var | 80 | 9 | 36 | 6 | 0.7 (0.5–1.2) | ||
| any var | 402 | 46 | 291 | 49 | 1.1 (0.9–1.4) | ||
| Lipid metabolism | SCARB1_03 | wt | 383 | 44 | 235 | 40 | 1.0 Ref. |
| g.IVS1−18462G>A | het | 381 | 44 | 290 | 49 | 1.2 (0.9–1.5) | |
| var | 101 | 12 | 66 | 11 | 1.0 (0.7–1.4) | ||
| any var | 482 | 56 | 356 | 60 | 1.1 (0.9–1.4) | ||
| Metabolism | SLC23A1_05 | wt | 813 | 94 | 545 | 92 | 1.0 Ref. |
| g.Ex8+22G>A | het | 50 | 6 | 46 | 8 | 1.5 (1.0–2.3) | |
| p.V264M | var | 2 | – | 0 | – | – | |
| any var | 52 | 6 | 46 | – | 1.5 (0.9–2.2) | ||
Analyses were adjusted for gender, age, smoking. Genotype data were missing for GSTZ1_02 on 153 controls, 158 cases; AKR1C3_35 on 29 controls, 29 cases; TYR_02 on 28 controls, 27 cases; SCARB1_03 on 28 controls, 26 cases; SLC23A1_05 on 28 controls, 26 cases
wt wildtype, het heterozygous, var variant, any variant heterozygous and variant, g. gene, Ex exon, p. protein